Khan M A, Abou-Halawa A S, Al-Robaee A A, Alzolibani A A, Al-Shobaili H A
Department of Otolaryngology, College of Medicine, Qassim University, PO Box 30109, Buraidah 51477, Qassim, Kingdom of Saudi Arabia.
J Laryngol Otol. 2010 Apr;124(4):397-401. doi: 10.1017/S002221510999171X. Epub 2009 Nov 25.
Many patients with allergic rhinitis are reluctant to use daily intranasal steroids for prolonged periods. A self-adjusted regimen which delivers reasonable control of allergic rhinitis may be more acceptable to such patients.
To compare the efficacy of daily use of mometasone furoate nasal spray, versus a self-adjusted regimen, in patients with chronic allergic rhinitis, in terms of symptom control and nasal volume change.
Ambulatory visits in an office setting.
Sixty patients with chronic allergic rhinitis were randomised: 30 were prescribed mometasone furoate nasal spray once daily for six weeks, while 30 were prescribed the same spray daily for one week, every alternate day for one week and then on a self-adjusted regimen for four weeks. Patients kept a symptom diary documenting sneezing, rhinorrhoea, nasal blockage and nasal itching. Acoustic rhinometry was used to measure the total nasal cavity volume at the first visit and at the end of the treatment period.
The total nasal score on treatment days showed an improvement in both groups, compared with baseline measurements. There was no significant difference in total nasal scores between the two groups, except on days 10 (p = 0.043), 20 (p = 0.008), 23 (p = 0.19), 30 (p = 0.008) and 37 (p = 0.000), when the daily group's total nasal score was significantly lower than the self-adjusted group's total nasal score, and on day 8 (p = 0.004), when the self-adjusted group's total nasal score was significantly lower than the daily group's total nasal score. Total nasal cavity volume significantly increased in both groups (p = 0.0001), with no statistically significant difference between the groups.
Self-adjusted dosage of mometasone furoate nasal spray gives reasonable control of allergic rhinitis (albeit with some 'breakthrough' symptoms). Patients should learn how to control these symptoms with the least number of steroid doses.
许多过敏性鼻炎患者不愿长期每日使用鼻内类固醇药物。一种能合理控制过敏性鼻炎的自我调整用药方案可能更容易被这类患者接受。
比较每日使用糠酸莫米松鼻喷雾剂与自我调整用药方案对慢性过敏性鼻炎患者症状控制和鼻腔容积变化的疗效。
门诊办公室就诊。
60例慢性过敏性鼻炎患者被随机分组:30例患者被处方每日一次使用糠酸莫米松鼻喷雾剂,持续六周;而另外30例患者被处方每日使用该喷雾剂一周,隔日使用一周,然后采用自我调整用药方案持续四周。患者记录症状日记,记录打喷嚏、流涕、鼻塞和鼻痒情况。在首次就诊时和治疗期结束时,使用鼻声反射仪测量鼻腔总体积。
与基线测量值相比,两组治疗日的总鼻部评分均有所改善。两组之间的总鼻部评分无显著差异,但在第10天(p = 0.043)、第20天(p = 0.008)、第23天(p = 0.19)、第30天(p = 0.008)和第37天(p = 0.000),每日用药组的总鼻部评分显著低于自我调整组的总鼻部评分;在第8天(p = 0.004),自我调整组的总鼻部评分显著低于每日用药组的总鼻部评分。两组的鼻腔总体积均显著增加(p = 0.0001),两组之间无统计学显著差异。
糠酸莫米松鼻喷雾剂的自我调整剂量能合理控制过敏性鼻炎(尽管会出现一些“突破性”症状)。患者应学会如何用最少剂量的类固醇药物控制这些症状。